In the same study, it was determined that serum FGF21 levels decreased by 13% after 6 months of angiotensin receptor blocker treatment in 72 patients with end-stage renal disease, and they stated that these findings suggest a possible connection between RAS and FGF21 [13]. This evidence concerns the gene FGF21 and stage 5 chronic kidney disease.